Literature DB >> 12444145

Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection.

Mark J Boaz1, Anele Waters, Shahed Murad, Philippa J Easterbrook, Annapurna Vyakarnam.   

Abstract

HIV immunity is likely CD4 T cell dependent. HIV-specific CD4 T cell proliferative responses are reported to correlate inversely with virus load and directly with specific CD8 responses. However, the phenotype and cytokine profile of specific CD4 T cells that correlate with disease is unknown. We compared the number/function of Gag p24-specific CD4 T cells in 17 HIV-infected long-term nonprogressors (LTNPs) infected for a median of 14.6 years with those of 16 slow progressors (SPs), also HIV infected for a median of 14 years but whose CD4 count had declined to <500 cells/ micro l. Compared with SPs, LTNPs had higher numbers of specific CD4s that were double positive for IFN-gamma and IL-2 as well as CD28 and IL-2. However, CD4 T cells that produced IL-2 alone (IL-2(+)IFN-gamma(-)) or IFN-gamma alone (IFN-gamma(+)IL-2(-)) did not differ between LTNPs and SPs. The decrease in p24-specific CD28(+)IL-2(+) cells with a concomitant increase of p24-specific CD28(-)IL-2(+) cells occurred before those specific for a non-HIV Ag, CMV. p24-specific CD28(-)IL-2(+) cells were evident in LTNPs and SPs, whereas the CMV-specific CD28(-)IL-2(+) response was confined to SPs. The difference between LTNPs and SPs in the Gag p24 IFN-gamma(+)IL-2(+) response was maintained when responses to total Gag (p17 plus p24) were measured. The percentage and absolute number of Gag-specific IFN-gamma(+)IL-2(+) but not of IFN-gamma(+)IL-2(-) CD4s correlated inversely with virus load. The Gag-specific IFN-gamma(+)IL-2(+) CD4 response also correlated positively with the percentage of Gag-specific IFN-gamma(+) CD8 T cells in these subjects. Accumulation of specific CD28(-)IL-2(+) helpers and loss of IFN-gamma(+)IL-2(+) CD4 T cells may compromise specific CD8 responses and, in turn, immunity to HIV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444145     DOI: 10.4049/jimmunol.169.11.6376

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  106 in total

1.  HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

Authors:  April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

2.  Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

Authors:  Lauren A Hirao; Ling Wu; Abhishek Satishchandran; Amir S Khan; Ruxandra Draghia-Akli; Adam C Finnefrock; Andrew J Bett; Michael R Betts; Danilo R Casimiro; Niranjan Y Sardesai; J Joseph Kim; John W Shiver; David B Weiner
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

3.  DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.

Authors:  Lara Vojnov; Alexander T Bean; Eric J Peterson; Maria J Chiuchiolo; Jonah B Sacha; Ferencz S Denes; Matyas Sandor; Deborah H Fuller; James T Fuller; Christopher L Parks; Adrian B McDermott; Nancy A Wilson; David I Watkins
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

4.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

5.  Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication.

Authors:  Thomas C Friedrich; Laura E Valentine; Levi J Yant; Eva G Rakasz; Shari M Piaskowski; Jessica R Furlott; Kimberly L Weisgrau; Benjamin Burwitz; Gemma E May; Enrique J León; Taeko Soma; Gnankang Napoe; Saverio V Capuano; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex
Journal:  Virology       Date:  2011-10-19       Impact factor: 3.616

7.  HIV vaccines: can CD4+ T cells be of help?

Authors:  Eva Van Braeckel; Geert Leroux-Roels
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

8.  A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults.

Authors:  Xia Jin; Mark J Newman; Stephen De-Rosa; Cristine Cooper; Evan Thomas; Michael Keefer; Jonathan Fuchs; William Blattner; Brian D Livingston; Denise M McKinney; Elizabeth Noonan; Allan Decamp; Olivier D Defawe; Margaret Wecker
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

9.  Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Authors:  S Pichyangkul; U Kum-Arb; K Yongvanitchit; A Limsalakpetch; M Gettayacamin; D E Lanar; L A Ware; V A Stewart; D G Heppner; P Mettens; J D Cohen; W R Ballou; M M Fukuda
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

10.  Timing constraints of in vivo gag mutations during primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Lauren Margolin; Jeannie Baca; Lemme Kebaabetswe; Raabya Rossenkhan; Caitlin Bonney; Michaela Herzig; David Nkwe; Sikhulile Moyo; Rosemary Musonda; Elias Woldegabriel; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.